A staggering 42% of adults in the U.S. are classified as obese, leading to significant health implications and soaring medical costs. The rise of obesity drugs, like Munjaro and Ozempic, highlights a growing market projected to reach $50 billion by 2030. The conversation reveals a troubling cycle where an industrial food complex fuels addiction to unhealthy foods, ultimately handing off individuals to a medical system that profits from their health struggles.
